AN2025

Adlai Nortye is a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, particularly in the fields of immune modulation and targeted therapy. The company's lead candidate is buparlisib (AN2025), an oral pan-PI3K inhibitor currently in a registrational Phase 3 trial for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Adlai Nortye's pipeline also includes palupiprant (AN0025), an EP4 antagonist, and AN4005, an oral small-molecule PD-L1 inhibitor, both in clinical development. The company leverages its proprietary platforms, PAINT-2D and ANEAT-Id, to discover and develop multi-specific antibodies and small molecules. With R&D centers in the U.S. and China, Adlai Nortye aims to transform cancer into a chronic and curable disease through its cocktail therapy strategy.